MX348178B - Método para purificar adamts13 recombinante y otras proteínas y sus composiciones. - Google Patents

Método para purificar adamts13 recombinante y otras proteínas y sus composiciones.

Info

Publication number
MX348178B
MX348178B MX2014008412A MX2014008412A MX348178B MX 348178 B MX348178 B MX 348178B MX 2014008412 A MX2014008412 A MX 2014008412A MX 2014008412 A MX2014008412 A MX 2014008412A MX 348178 B MX348178 B MX 348178B
Authority
MX
Mexico
Prior art keywords
protein
adamts13
methods
compositions
sample
Prior art date
Application number
MX2014008412A
Other languages
English (en)
Inventor
Hasslacher Meinhard
Mitterer Artur
Fiedler Christian
Mayer Christa
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX348178B publication Critical patent/MX348178B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Sustainable Development (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Water Supply & Treatment (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un método in vitro para inactivar contaminantes de virus con envoltura lipídaca en una solución de proteínas en el procedimiento de purificación de una proteína terapéutica, caracterizado por el método porque la proteína terapéutica es inmovilizada en un soporte in vitro de la solución.
MX2014008412A 2009-07-31 2010-08-02 Método para purificar adamts13 recombinante y otras proteínas y sus composiciones. MX348178B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23030809P 2009-07-31 2009-07-31
PCT/EP2010/061192 WO2011012726A2 (en) 2009-07-31 2010-08-02 Method for purifying recombinant adamts13 and other proteins and compositions thereof

Publications (1)

Publication Number Publication Date
MX348178B true MX348178B (es) 2017-05-29

Family

ID=42588355

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014008412A MX348178B (es) 2009-07-31 2010-08-02 Método para purificar adamts13 recombinante y otras proteínas y sus composiciones.
MX2012001263A MX2012001263A (es) 2009-07-31 2010-08-02 Metodo para purificar adamts13 recombinante y otras proteinas y sus composiciones.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012001263A MX2012001263A (es) 2009-07-31 2010-08-02 Metodo para purificar adamts13 recombinante y otras proteinas y sus composiciones.

Country Status (22)

Country Link
US (4) US8945895B2 (es)
EP (3) EP4299735B1 (es)
JP (6) JP5907869B2 (es)
KR (7) KR20190122272A (es)
CN (3) CN107988192A (es)
AU (1) AU2010277491B2 (es)
CA (2) CA2769362A1 (es)
CO (1) CO6612194A2 (es)
DK (1) DK2459715T3 (es)
EA (3) EA023783B1 (es)
ES (3) ES2763207T3 (es)
HR (1) HRP20192303T1 (es)
HU (1) HUE046909T2 (es)
IN (1) IN2012DN00907A (es)
LT (1) LT2459715T (es)
MX (2) MX348178B (es)
NZ (2) NZ620988A (es)
PL (2) PL3211077T3 (es)
PT (1) PT2459715T (es)
SG (2) SG178175A1 (es)
SI (1) SI2459715T1 (es)
WO (1) WO2011012726A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008113011A2 (en) 2007-03-14 2008-09-18 Ligocyte Pharmaceuticals, Inc. Virus like particle purification
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
EP3456837A3 (en) * 2011-03-14 2019-04-24 Catalent Pharma Solutions, LLC Decorin compositions and use thereof
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9096648B2 (en) 2011-08-19 2015-08-04 Emd Millipore Corporation Methods of reducing level of one or more impurities in a sample during protein purification
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
BR112014031842B1 (pt) * 2012-06-21 2020-09-15 Baxalta GmbH Método para remover um contaminante viral de uma preparação
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CN112126634A (zh) * 2013-01-09 2020-12-25 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US8859252B1 (en) 2014-01-02 2014-10-14 Aerial Biopharma, Llc Prostatic acid phosphatase, compositions comprising the same, and methods for producing and/or purifying the same
WO2015120056A1 (en) 2014-02-04 2015-08-13 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
IL264372B2 (en) 2016-08-04 2024-05-01 Baxalta Inc Adamts13 for use in treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
JP2021519339A (ja) * 2018-04-03 2021-08-10 メルク パテント ゲーエムベーハー Ｃｅｘクロマトグラフィー媒体及び生物製剤供給原料からの標的タンパク質の低塩溶出
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
US11912741B2 (en) * 2019-04-03 2024-02-27 Genzyme Corporation Continuous production of recombinant proteins
WO2021067668A1 (en) 2019-10-04 2021-04-08 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
US11821000B2 (en) * 2020-11-10 2023-11-21 Dionex Corporation Method of separating viral vectors
WO2023052556A1 (en) * 2021-09-30 2023-04-06 Ichnos Sciences SA Methods of inactivating viral contaminants with a mixture of solvent and detergent
MX2024010855A (es) 2022-03-07 2024-09-11 Takeda Pharmaceuticals Co Produccion cromatografica de afinidad de productos clinicos de inmunoglobulina g (igg) humana.
TW202400224A (zh) * 2022-05-10 2024-01-01 南韓商綠十字股份有限公司 用於冷凍乾燥血漿蛋白之新穎液體調配物
WO2023219378A1 (ko) * 2022-05-10 2023-11-16 주식회사 녹십자 혈장 단백질에 대한 신규한 액상 제형물
WO2025181559A1 (en) * 2024-02-29 2025-09-04 Sloiron, Inc. Methods for determining the amount of encapsulated and free iron in a sample
US20250334572A1 (en) * 2024-04-26 2025-10-30 Waters Technologies Corporation Host cell protein detection using lateral flow devices

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239854A (en) * 1978-04-24 1980-12-16 Sumitomo Chemical Company, Limited Enzyme-immobilization carriers and preparation thereof
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5283182A (en) * 1986-09-17 1994-02-01 Beecham Group Plc Preparation of immobilized hydantoinase stabilized with divalent metal ions
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
FR2681867B1 (fr) 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
JP4260877B2 (ja) 1992-03-02 2009-04-30 バイオエング・インコーポレーテッド ウイルスの不活性化方法
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5578480A (en) * 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
GB9503750D0 (en) * 1995-02-24 1995-04-12 Common Services Agency Thrombin preparation
US5688912A (en) 1995-09-22 1997-11-18 Bayer Corporation Peptide ligands which bind to von willebrand factor
US5786458A (en) * 1996-06-28 1998-07-28 Bayer Corporation Selective stabilization of protein during viral inactivation
US5831003A (en) 1996-06-28 1998-11-03 Bayer Corporation Peptides which bind to prothrombin and thrombin
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
JP4707231B2 (ja) 1998-06-10 2011-06-22 スタテンズ セーラム インスティテュート マンナン結合レクチンを製造するための精製方法及びｍｂｌ医薬品
US6251860B1 (en) * 1998-07-07 2001-06-26 Suomen Punainen Risti Veripalvelu Pharmaceutical preparations
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
US6451978B2 (en) * 2000-01-21 2002-09-17 Biovitrum Ab Purification of antithrombin-III-α and β
IL136552A (en) 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
WO2002031163A1 (en) * 2000-10-11 2002-04-18 Kazusa Dna Research Institute Foundation Novel adamts family polypeptide and gene encoding the same
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
CN1230526C (zh) * 2001-02-27 2005-12-07 成都夸常科技有限公司 一种除去作为病毒灭活剂的有机溶剂和/或去污剂的方法
AU2002336367A1 (en) 2001-08-16 2003-03-03 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
JP2003144154A (ja) * 2001-11-14 2003-05-20 Mitsubishi Pharma Corp 新規なａｄａｍｔｓファミリーポリペプチドおよびそれをコードする遺伝子
US20060110407A1 (en) * 2001-12-05 2006-05-25 Shelley Stopera Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
US20030133829A1 (en) 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
ES2322945T5 (es) 2001-12-21 2012-10-17 Immunex Corporation Métodos para purficación de proteína
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
GB0216002D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
US7718763B2 (en) * 2002-10-18 2010-05-18 Japan As Represented By The President Of National Cardiovascular Center Substrate polyeptides for von Willebrand factor cleaving protease ADAMTS-13
JP3983260B2 (ja) 2003-07-09 2007-09-26 塩野義製薬株式会社 アトピー性皮膚炎誘引物質
CA2487673C (en) * 2003-12-02 2010-11-02 F. Hoffmann-La Roche Ag Improved method for the recombinant production and purification of protein kinases
GB0405330D0 (en) * 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
EP1740285A4 (en) * 2004-04-13 2007-07-04 Sangart Inc METHOD AND COMPOSITIONS FOR SIMULTANEOUS ISOLATION OF HEMOGLOBIN FROM RED BLOOD BODIES AND INACTIVATION OF VIRUSES
WO2005121163A2 (en) 2004-06-07 2005-12-22 Upfront Chromatography A/S Isolation of plasma or serum proteins
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7515392B2 (en) 2004-07-28 2009-04-07 Texas Instruments Incorporated High voltage circuits implemented using low voltage transistors
DE102004044419B4 (de) * 2004-09-14 2010-04-15 Biotest Ag Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie
JP2006083044A (ja) 2004-09-17 2006-03-30 Hitachi Ltd ガラス部材
US20090215699A1 (en) * 2005-01-05 2009-08-27 Foundation For Fatel Rare Diseases Pharmaceutically Active Antiviral Peptides
US20060193966A1 (en) * 2005-02-28 2006-08-31 Shaowen Wu Multi-anion treated soy proteins and methods for preparation thereof
ATE544866T1 (de) 2005-06-17 2012-02-15 Baxter Int Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
US7506514B2 (en) 2005-06-30 2009-03-24 United Technologies Corporation Augmentor fuel conduit bushing
US20090215025A1 (en) * 2005-12-07 2009-08-27 Technische Universitat Munchen Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
JP5067917B2 (ja) 2005-12-28 2012-11-07 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の分離精製方法
ES2386574T3 (es) 2006-02-16 2012-08-23 Mitsubishi Chemical Medience Corporation Procedimiento de detección de afección en paciente con alteración de la consciencia
US7468258B2 (en) 2006-03-07 2008-12-23 Wake Forest University Health Sciences Self-quenching homofluorophore compositions for detecting enzyme activity
WO2008057074A1 (en) * 2006-11-06 2008-05-15 Millipore Corporation Method of flow-through chromatography
US8669045B2 (en) 2007-02-13 2014-03-11 Ajinomoto Co., Inc. Method for inactivating viruses with slightly acidic arginine
EP2374878B1 (en) 2007-06-22 2015-08-19 The Chemo-Sero-Therapeutic Research Institute Novel adamts-13 mutant
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
CN101730707B (zh) 2007-07-11 2014-12-17 诺沃-诺迪斯克有限公司 使用混合式或多模式树脂来纯化因子ⅷ
MX2010002249A (es) * 2007-08-31 2010-03-17 Amgen Inc Formulacion de proteina de estado solido.
US20090130714A1 (en) * 2007-09-24 2009-05-21 Reliance Life Sciences Pvt.Ltd. Process for purifying recombinanat tissue plasminogen activator (TPA)
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof

Also Published As

Publication number Publication date
CN107988192A (zh) 2018-05-04
KR20170096061A (ko) 2017-08-23
CN102482660A (zh) 2012-05-30
EA023783B1 (ru) 2016-07-29
HRP20192303T1 (hr) 2020-10-02
US20110081700A1 (en) 2011-04-07
WO2011012726A2 (en) 2011-02-03
EP3211077B1 (en) 2024-09-25
LT2459715T (lt) 2020-01-10
ES3000382T3 (en) 2025-02-28
JP2013500711A (ja) 2013-01-10
WO2011012726A3 (en) 2011-03-31
CA2769362A1 (en) 2011-02-03
US11661593B2 (en) 2023-05-30
EA201270214A1 (ru) 2012-08-30
EA034292B1 (ru) 2020-01-24
JP6216930B2 (ja) 2017-10-25
SI2459715T1 (sl) 2020-01-31
AU2010277491A2 (en) 2012-06-21
EP4299735B1 (en) 2025-05-21
US20150104849A1 (en) 2015-04-16
PT2459715T (pt) 2020-01-09
JP2022171925A (ja) 2022-11-11
KR20220066435A (ko) 2022-05-24
DK2459715T3 (da) 2020-01-06
SG193855A1 (en) 2013-10-30
JP2015147815A (ja) 2015-08-20
US12492390B2 (en) 2025-12-09
EP4299735A3 (en) 2024-04-24
EA201500952A1 (ru) 2016-05-31
MX2012001263A (es) 2012-05-22
EP2459715B1 (en) 2019-10-02
EP2459715A2 (en) 2012-06-06
BR112012002140A2 (pt) 2015-09-15
US20230242897A1 (en) 2023-08-03
JP5907869B2 (ja) 2016-04-26
KR20120053013A (ko) 2012-05-24
JP2021004265A (ja) 2021-01-14
CA2916508A1 (en) 2011-02-03
NZ620988A (en) 2015-07-31
EA201992487A1 (ru) 2020-05-31
EP3211077A1 (en) 2017-08-30
KR101769634B1 (ko) 2017-08-18
US8945895B2 (en) 2015-02-03
CN107267490A (zh) 2017-10-20
ES2763207T3 (es) 2020-05-27
HUE046909T2 (hu) 2020-04-28
EP4299735A2 (en) 2024-01-03
KR101883610B1 (ko) 2018-07-30
PL2459715T3 (pl) 2020-04-30
IN2012DN00907A (es) 2015-04-03
AU2010277491A1 (en) 2012-02-16
KR20200146042A (ko) 2020-12-31
AU2010277491B2 (en) 2015-12-17
SG178175A1 (en) 2012-03-29
NZ597756A (en) 2014-03-28
KR20180087463A (ko) 2018-08-01
ES3039686T3 (en) 2025-10-23
US20260062691A1 (en) 2026-03-05
KR20190122272A (ko) 2019-10-29
KR20230170815A (ko) 2023-12-19
JP2016222724A (ja) 2016-12-28
PL3211077T3 (pl) 2025-04-14
CO6612194A2 (es) 2013-02-01
JP2018203781A (ja) 2018-12-27

Similar Documents

Publication Publication Date Title
MX2012001263A (es) Metodo para purificar adamts13 recombinante y otras proteinas y sus composiciones.
AU2016222301A1 (en) Isolation and purification of antibodies using Protein A affinity chromatography
CY1123952T1 (el) Απομονωση και καθαρισμος αντισωματων αντι-il-13 με την χρηση χρωματογραφιας χημικης συγγενειας πρωτεινης α
NZ781138A (en) Anti-vegf protein compositions and methods for producing the same
WO2006041934A3 (en) Methods and compositions for improving recombinant protein production
JP2013500711A5 (es)
RU2011137030A (ru) Способы очистки малых модулярных иммунофармацевтических белков
PE20150720A1 (es) Purificacion de iduronato-2-sulfatasa
MX2020003798A (es) Metodos para la purificacion de arilsulfatasa a.
EA201591807A1 (ru) Способы изготовления образцов для контроля содержания с-концевого лизина, галактозы и сиаловой кислоты в рекомбинантных белках
MX2024009755A (es) Metodos de purificacion de un producto.
WO2008085962A3 (en) Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
CA2551345C (fr) Procede de separation des proteines fibrinogenes, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
SG157346A1 (en) Improved purification of collagenases from clostridium histolyticum liquid culture
WO2012024400A3 (en) Elution of proteins from hydroxyapatite resins without resin deterioration
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
DE69435020D1 (en) Protein-tyrosin-phosphatase ptp-s31
WO2006113475A3 (en) Methods and compositions to modulate adhesion and stress tolerance in bacteria
ATE496133T1 (de) Affinitätspolypeptid zur reinigung von rekombinanten proteinen
WO2006091535A3 (en) Novel egg receptors for sperm proteins
ATE553194T1 (de) Verfahren zur dipeptidherstellung
MX2021016092A (es) Metodos de purificacion de proteinas.
Moriguchi et al. Reduction of plant-specific arabinogalactan-type O-glycosylation by treating tobacco plants with ferrous chelator 2, 2′-dipyridyl
AU2014230101B2 (en) Purification method for vitamin K dependent proteins by anion exchange chromatography
JP2015156821A (ja) ヒト膵臓特異的リボヌクレアーゼ１及びその分離方法